Advanced Filters
noise

vaccines Clinical Trials

A listing of vaccines medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 530 clinical trials

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).

21 years of age All Phase 2
J Johan CHANAL, Dr

Nonavalent HPV Vaccine in the Treatment of Difficult-to-treat Palmo-plantar Warts

Cutaneous viral warts are very common and are caused by the human papilloma virus (HPV). Most people experience warts in one form or another at some point in their lives. Cutaneous warts are related to different types of HPV. For the palms and soles, HPV 2 has been the most …

15 years of age All Phase 3
M Mary Reid, PhD

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

This early phase I trial studies the side effects of a vaccine called CIMAvax-EGF and to see how well it works in preventing lung cancer from developing in patients at high risk for lung cancer or coming back (recurrence) in stage IB-IIIA non-small cell lung cancer survivors. In many cancers …

50 - 79 years of age All Phase N/A
S Simon Karanja, PhD

Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women

Iron deficiency (ID) anemia (IDA) is a global public health problem, with the highest prevalence in Africa. Vaccines often underperform in low- and middle- income countries (LMIC), and undernutrition, including ID, likely plays a role. Recent studies have shown the importance of iron status in vaccine response. Intravenous iron given …

18 - 49 years of age Female Phase N/A

A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol

The goal of this clinical trial is to study the safety of a new inhaled vaccine to prevent COVID infection and learn about the immune responses that are made in the lungs and the blood after vaccination. Participants will be randomized (like the toss of a coin) to receive the …

18 - 65 years of age All Phase 2
Y Yong yi Zeng

Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection

This study is a single-arm, open-label, exploratory clinical trial, with the primary objective to evaluate the efficacy and safety of the Neoantigen Vaccine plus capecitabine for the treatment of high-intermediate risk recurrent intrahepatic cholangiocarcinoma

18 - 75 years of age All Phase N/A
G Guang Ning, Professor

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging. Previous genomic profiling studies showed they presented a number of somatic mutations. The tumors Individualized mRNA neoantigen vaccine provide a promising solution since a significant portion of these …

18 years of age All Phase N/A

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

In this challenge study, the bioconjugate candidate vaccine Shigella4V2 will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella sonnei strain compared to participants receiving placebo.

18 - 50 years of age All Phase 2
M Michael A Huang, M.D.

Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors

The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with brain tumors that have returned or have been resistant to treatment.

- 25 years of age All Phase 1
H Heinz Lubenau, Dr

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

Phase I/II, multicenter, open-label, single-arm trial in triple-negative breast cancer patients under first-line neoadjuvant therapy with approved standard of care anti-PD-1 monoclonal antibody (PD-1 inhibitor), epirubicin/cyclophosphamide chemotherapy, and nab-paclitaxel therapy. NECVAX-NEO1 treatment in addition to standard of care anti-PD1 monoclonal antibody therapy can be prolonged after breast cancer surgery for …

18 years of age All Phase 1/2

Simplify language using AI